Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2)
Neutralization
Human
IgG1, kappa
CC40.8
SARS-CoV-2(2019-nCoV)
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Human
IgG1
CV3-25
SARS-CoV-2(2019-nCoV)
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Human
IgG1
WS6
E. coli
Q9H2K2
Ser959-Gly1166
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Homo sapiens (Human)
E. coli
P35442
Asp968-Ile1172
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Homo sapiens (Human)
E. coli
P0DTC2
Ser686-Pro1213
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2)
Neutralization
Human
IgG1, kappa
CV3-25
Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2)
Neutralization
Human
IgG1, kappa
S2P6
Middle East respiratory syndrome-related coronavirus (isolate UnitedKingdom/H123990006/2012) (MERS-CoV) (Betacoronavirus England 1)
ELISA, FCM, IF, Neutralization, SPR
Human
IgG1
G4
Middle East respiratory syndrome-related coronavirus (isolate UnitedKingdom/H123990006/2012) (MERS-CoV) (Betacoronavirus England 1)
ELISA, FCM, Neutralization, SPR
Human
IgG1
MERS-27